(NASDAQ: CELC) Celcuity's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.73%.
Celcuity's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast CELC's revenue for 2025 to be $494,333,586, with the lowest CELC revenue forecast at $259,201,131, and the highest CELC revenue forecast at $729,466,040. On average, 4 Wall Street analysts forecast CELC's revenue for 2026 to be $2,658,181,656, with the lowest CELC revenue forecast at $901,649,649, and the highest CELC revenue forecast at $5,043,313,435.
In 2027, CELC is forecast to generate $10,673,717,431 in revenue, with the lowest revenue forecast at $7,497,207,571 and the highest revenue forecast at $16,018,629,896.